Jon Bilous / Shutterstock.com
4 May 2023AmericasLiz Hockley
Vizgen accuses Harvard and 10x of patent licence cover-up
Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
5 May 2022 Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023 Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023 Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.
Editor's picks
Editor's picks
Big Pharma
5 May 2022 Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023 Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023 Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.
Big Pharma
5 May 2022 Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.
Biotechnology
8 June 2023 Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.
Big Pharma
13 July 2023 Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.